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Abstract Observational studies suggest that host factors
are associated with breast cancer risk. The influence of
obesity, vitamin-D status, insulin resistance, inflammation,
and elevated adipocytokines in women at high risk of
breast cancer is unknown. The NSABP-P1 trial population
was used for a nested case–control study. Cases were
drawn from those who developed invasive breast cancer
and controls selected from unaffected participants (B4 per
case) matched for age, race, 5 year Gail score, and geo-
graphic location of clinical center as a surrogate for lati-
tude. Fasting serum banked at trial enrolment was assayed
for 25-hydroxy vitamin-D (25OHD), insulin, leptin
(adipocytokine), and C-reactive protein (CRP, marker of
inflammation). Logistic regression was used to test for
associations between study variables and the risk of inva-
sive breast cancer. Two hundred and thirty-one cases were
matched with 856 controls. Mean age was 54, and 49%
were premenopausal. There were negative correlations for
25OHD with body mass index (BMI), insulin, CRP, and
leptin. BMI C 25 kg/m2 was associated with higher breast
cancer risk (odds ratio [OR] 1.45, p = 0.02) and tamoxifen
treatment was associated with lower risk (OR = 0.44,
p \ 0.001). Suboptimal 25OHD (\72 nmol/l) did not
influence breast cancer risk (OR = 1.06, p = 0.76). When
evaluated as continuous variables, 25OHD, insulin, CRP,
and leptin levels were not associated with breast cancer risk
(all p [ 0.34). In this high risk population, higher BMI was
associated with a greater breast cancer risk. Serum levels of
25OHD, insulin, CRP, and leptin were not independent
predictors of either breast cancer risk or tamoxifen benefit.
Keywords Breast cancer  Vitamin-D  Obesity 
Cancer prevention  Tamoxifen
Introduction
Numerous risk factors for the development of breast cancer
have been identified and quantified [4]. However, up to
60% of breast cancers arise in the absence of known risk
factors [35]. Furthermore, established risk factors do not
always account for all the attributable risk [4]. Therefore,
there is a need to identify and validate new risk factors in
women, regardless of the presence of recognized risk fac-
tors. Women could then be better advised on their indi-
vidual risk and the need for risk-reducing strategies.
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A considerable body of literature has examined the
inverse association between blood levels of vitamin-D and
overall cancer risk as well as the potential role of vitamin-
D in cancer prevention [24, 28]. The greatest magnitude of
association of breast cancer risk and vitamin-D comes from
geographic studies which show higher incidence in patients
residing at high latitudes [12]. Unfortunately, such studies
do not provide direct evidence of an association of vitamin-
D with breast cancer risk. Other data linking lower blood
levels of vitamin-D to breast cancer risk are inconsistent
[41] (Table 1).
A number of other host-related factors such as obesity
and diet have also been postulated as breast cancer risks
[26, 31]. The association of obesity and the development of
breast cancer in post-menopausal women is relatively
strong [27]; a weaker association of central obesity with the
development of breast cancer exists in pre-menopausal
women [27]. The mechanisms underlying this risk remain
unclear. Possible explanations are elevated estrogen levels,
insulin resistance with consequential hyperinsulinemia, and
higher levels of insulin-like-growth-factor (IGF) [42]. Adi-
pose tissue may directly influence tumor growth or differen-
tiation by secretion of adipose tissue-derived hormones called
adipocytokines, including adiponectin and leptin [30].
Many risk factors for breast cancer are inter-related. For
instance, obesity and vitamin-D deficiency are associated
Table 1 Studies assessing blood levels of vitamin-D metabolites and breast cancer risk
Study Study design Number of cases/
controls
Comparison OR or RR
p value
Blood collected before diagnosis of breast cancer
Bertone-Johnson [5] Nested case–control 701/724 Plasma 25-hydroxy vitamin-D 1.37
(Nurses’ health study) Quintile 1 vs. 5 p = 0.06
Freedman [22] Nested case–control 1005/1005 Serum 25-hydroxy vitamin-D 0.96
(prostate, lung, colorectal and
ovarian cancer screening trial)
Quintile 1 vs. 5 p = 0.81
Chlebowski [8] Nested case–control 1067/1067 Plasma 25-hydroxy vitamin-D 1.22
(Women’s health initiative) Quintile 1 vs. 5 p = 0.20*
McCullough [37] Nested case–control 516/516 Serum 25-hydroxy vitamin-D 0.92
(Cancer prevention study II) Quintile 1 vs. 5 p = 0.60*
Engel [17] Nested case–control 636/1272 Serum 25-hydroxy vitamin-D 1.37
(French E3 N cohort) \19.8 vs. [27 ng/ml p = 0.02*
Almquist [3] Nested case–control 764/764 Serum 25-hydroxy vitamin-D 1.08
(Malmo¨ diet and cancer study) Quartile 1 vs. 4 p = 0.71*
Veldhuis [48] Cross-sectional study 56/829 Serum 25-hydroxy vitamin-D 1.43
(Osteoporosis and fracture clinic) \50 vs. C50 nmol/l p = 0.18
Eliassen [16] Nested case–control 613/1218 Serum 25-hydroxy vitamin-D 1.20
(Nurses health study II) Quartile 1 vs. 4 p = 0.32
Blood collected after diagnosis of breast cancer
Lowe [34] Hospital-based case–control 179/170 Plasma 25-hydroxy vitamin-D 5.83
(UK) \50 vs. [150 nmol/l p \ 0.001
Abbas [1] Population-based case–control 289/595 Plasma 25-hydroxy vitamin-D 2.22
(Pre-menopusal women, Germany) \30 nmol/l vs. C60 nmol/l p \ 0.001*
Abbas [2] Population-based case–control 1394/1365 Serum 25-hydroxy vitamin-D 3.23
(Post-menopusal women, Germany) \30 vs. C75 nmol/l p \ 0.001*
Crew [11] Population-based case–control 1026/1075 Plasma 25-hydroxy vitamin-D 1.79
(Long Island, NY) \20 vs. [40 ng/ml p = 0.002*
Rejnmark [40] Nested case–control 142/420 Serum 25-hydroxy vitamin-D 1.92
(Denmark) Tertile 1 vs. 3 p \ 0.05
Yao [51] Hospital-based case–control 220/156 Serum 25-hydroxy vitamin-D 2.70
(USA) \20 vs. C30 ng/ml p \ 0.001*
OR odds ratio, RR risk ratio, NS not significant
* Statistical test for trend
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with insulin resistance, inflammation, and elevated adipocy-
tokines [25, 44, 47]. Cigarette smoking is associated with
insulin resistance [21] as well as increased inflammation [23].
The primary aim of this study was to explore circulating
25-hydroxy vitamin-D, an indicator of vitamin-D status, as
a predictor of breast cancer risk after adjustment for
potential confounding baseline factors. Secondary aims
included assessment of the relationships between obesity,
25-hydroxy vitamin-D levels, insulin resistance, C-reactive
protein (CRP, a marker of inflammation), and leptin
(an adipocytokine), and to evaluate whether these factors
were associated with differential benefit from chemopre-
vention in a prospective cohort of patients enrolled in the
National Surgical Adjuvant Breast and Bowel Project
Protocol (NSABP) P1. We hypothesized that 25-hydroxy
vitamin-D levels would be inversely related to breast
cancer risk in women receiving both tamoxifen and pla-
cebo, that the effect of tamoxifen would be modified by
25-hydroxy vitamin-D levels, and that associations of
25-hydroxy vitamin-D levels with breast cancer risk would
be independent of the effects of insulin, adipocytokines,
and inflammatory markers.
Materials and methods
Study population
A case–control study design nested in the NSABP-P1 trial
population was performed. Between 1992 and 1997, the
NSABP-P1 trial randomized 13,388 women, age 35 years
or older and at increased risk for breast cancer [Gail model
5 year score C 1.66% or history of lobular carcinoma in
situ (LCIS)] to 5 years of tamoxifen (20 mg daily) or
matched placebo [19]. Prior to randomization, all partici-
pants provided fasting blood specimens which were pro-
cessed into 1-ml aliquots and frozen at -80C. The trial
was stopped early after a median follow-up of 54.6 months
as the data-monitoring committee determined that the 49%
relative reduction in risk of invasive breast cancer had met
pre-specified stopping rules. At that time, treatment allo-
cation was unblinded and placebo participants were offered
tamoxifen or the opportunity to participate in a subsequent
chemoprevention trial. A total of 270 participants devel-
oped invasive breast cancer before the study was
unblinded.
Cases included participants who developed invasive
breast cancer before unblinding, had sufficient quantity and
quality of stored blood samples, and provided additional
consent for the use of these materials for further research.
Controls included participants who did not develop inva-
sive or non-invasive breast cancer during the course of
follow-up before unblinding and were matched for age
(±5 years), 5 year Gail score (B2.24%, 2.25–3.48%,
C3.49%), race, and participant’s clinical center as a sur-
rogate for latitude of residence. Up to four matched con-
trols for each invasive breast cancer were selected. The
study was approved by the institutional ethics boards of
both Mount Sinai Toronto and NSABP.
Laboratory assays
Frozen aliquots of serum measuring 1 ml were obtained from
the NSABP biospecimen repository. Specimens were thawed
and then analyzed for 25-hydroxy vitamin-D, insulin, and
CRP on a single run. Testing for leptin was carried out on a
separate run. 25-Hydroxy vitamin-D was assayed by the
Liaison 25-hydroxy vitamin-D total assay chemiluminescent
immunoassay (Diasorin Inc, Mississauga, ON, intra- and
inter-assay co-efficient of variability (CV) were 6.7% and
11.7–18.4%, respectively). The range of detection for this
platform was 10–375 nmol/l. Insulin was assayed by the
Roche Diagnostics electrochemiluminescence immunoassay
(Roche Diagnostics Canada Inc, Laval, QC, intra- and inter-
assay CV were both \3.7%). This assay has an analyzable
range of 1.39–6,945 pmol/l. CRP was assayed by the Roche
Diagnostics particle-enhanced immunoturbidimetric assay
(Roche Diagnostics Canada Inc, Laval, QC, intra and inter-
assay CV were 1.8% and 5.2–5.7%, respectively) which can
detect levels between 0.1 and 20 mg/l. Finally, leptin was
measured by the Linco sandwich enzyme linked immuno-
sorbent assay (Millipore Inc, Billerica, MA, intra- and inter-
assay CV were 3.8 and 4.4%, respectively). This platform had
a range of detection between 0.5 and 100 ng/ml.
Review and meta-analysis
In order to place the results of this study in context, our
data were pooled together with other published data
exploring 25-hydroxy vitamin-D and breast cancer risk.
MEDLINE (Host: PubMed) was searched and a systematic
review of the literature was carried out and trials reporting
association between breast cancer and serum levels of
25-hydroxy vitamin-D were included. There were two pre-
planned cohorts for this meta-analysis: (1) studies where
blood was collected after the diagnosis of breast cancer and
(2) studies where blood was collected before the diagnosis
of breast cancer. Odds ratios (ORs) were extracted from
individual studies, weighted using the generic inverse
variance approach, and pooled using the DerSimonian and
Laird random-effects method [15].
Statistical analysis
Spearman’s rho was used to assess the correlation of
25-hydroxy vitamin-D levels with BMI, insulin, CRP, and
Breast Cancer Res Treat (2012) 133:1077–1088 1079
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leptin levels, and to assess the correlation between
25-hydroxy vitamin-D levels and the latitude of clinical
center. The magnitude of correlation was assessed as
described by Burnand et al. [6]. The distribution of cases
by participant and tumor characteristics was determined
and differences between the distributions for those with
25-hydroxy vitamin-D levels \72 nmol/l and those with
levels C72 nmol/l were compared using the v2 test. This
prior selected value for optimal blood levels of 25-hydroxy
vitamin-D was based on the best available data at study
initiation [13, 29]. It pre-dated the Institute of Medicine
report suggesting a cut-off of 50 nmol/l [43]. In view of the
inconsistent data regarding optimal cut-offs for optimal
25-hydroxy vitamin-D levels, in initial analyses,
25-hydroxy vitamin-D levels were evaluated as a dichot-
omized parameter cut at C72 nmol/l. Analyses were then
repeated using log-transformed 25-hydroxy vitamin-D
levels as a continuous variable. The association between
serum 25-hydroxy vitamin-D levels and the risk of devel-
oping invasive breast cancer was evaluated using condi-
tional logistic regression. The nature of the association was
evaluated, initially in the univariable setting, and then in
the multivariable setting with adjustment for potential
confounding baseline factors including tamoxifen treat-
ment, BMI, history of osteoporosis, cigarette smoking, and
exogenous hormone use. Interaction between tamoxifen
treatment and levels of serum markers was also assessed
during multivariable modeling. The independent associa-
tion with breast cancer risk was also evaluated for baseline
serum levels of insulin, CRP, and leptin, all assessed as
log-transformed continuous variables. When using contin-
uous variables, ORs compared the midpoint of the upper
quartile to the midpoint of the lower quartile. Statistical
significance of parameters included in the regression
models was assessed using the likelihood ratio test. Sta-
tistical significance of all testing was based on a two-sided
test using an alpha level of 0.05.
Results
Data were available for 231 case participants (Fig. 1). Four
matched controls were obtained for 196 of the cases
(84.8%), three matched controls for 12 cases (5.2%), two
matched controls for 13 cases (5.6%), and for ten cases
(4.3%) only one matched control was obtained. Thus, the
total study population comprised 1,087 participants (231
cases and 856 matched controls). The mean age was
53.6 years (standard deviation [SD] 8.7); mean BMI was
27.2 kg/m2 (SD 5.7); and mean Gail model 5 year risk was
4.08% (SD 2.72). Forty-nine percent were pre-menopausal.
Demographic factors for cases and controls and tumor
characteristics for cases are shown in Table 2. Other than
treatment, the only factor that showed a statistically sig-
nificant difference between cases and controls was BMI.
The percent of participants demonstrating sufficient levels
(C72 nmol/l) of 25-hydroxy vitamin-D levels was 24.2%
among the cases and 27.8% among the controls.
Descriptive analysis of serum variables and correlations
between variables are shown in Table 3 and correlations
between BMI and serum variables are shown in Fig. 2.
There was no correlation between 25-hydroxy vitamin-D
levels and latitude of the participant’s clinical center
(rho = -0.02; p = 0.45). There were weak positive cor-
relations between age and insulin, CRP and leptin levels,
and a weak negative correlation with 25-hydroxy vitamin-
D. The rho for age and insulin, CRP, leptin, and
25-hydroxy vitamin-D were 0.15, 0.20, 0.12, and -0.11,
respectively (Supplementary Figure).
The results of univariable and multivariable conditional
logistic regression modeling of the risk of developing inva-
sive breast cancer when using 25-hydroxy vitamin-D as a
dichotomous variable are shown in Table 4. The univariable
OR for suboptimal vitamin-D status (serum 25-hydroxy
vitamin-D \72 nmol/l) was 1.25, 95% confidence intervals
(CI) were 0.88–1.77, (p = 0.21; Table 4-Model 1). When
adjusting for tamoxifen treatment and BMI (Table 4-Model
3), the OR for the effect of suboptimal 25-hydroxy vitamin-D
decreased to 1.06 (95% CI 0.73–1.53, p = 0.76). In this
model, tamoxifen treatment showed a 56% reduction in the
odds of invasive breast cancer (OR = 0.44, 95% CI
0.32–0.61, p \ 0.001); and the OR for BMI C 25 kg/m2 was
1.45 (95% CI 1.06–2.00, p = 0.02). When BMI was assessed
as three discrete categories (\25.0, 25.0–29.9, and C30.0 kg/
m2) in this multivariable model, there was little change to the
effect of suboptimal 25-hydroxy vitamin-D (OR = 1.07,
p = 0.73, Table 4-Model 4).
In univariable analysis as a continuous variable,
25-hydroxy vitamin-D again did not show a statistically
significant association with invasive breast cancer (OR
for upper versus lower quartile = 0.77, 95% CI
0.55–1.06, p = 0.11; Table 5, first row). When assessed
as a continuous variable and adjusted for treatment and
BMI (Table 5, fourth from bottom row), 25-hydroxy
vitamin-D, did not show a statistically significant
association with invasive breast cancer (OR for upper
versus lower quartile = 0.86, 95% CI 0.62–1.21,
p = 0.40).
There was no evidence of interaction between tamoxifen
treatment and any serum markers. The p value for inter-
action between tamoxifen treatment and 25-hydroxy vita-
min-D, insulin, CRP, and leptin were 0.52, 0.49, 0.83, and
0.68, respectively.
History of osteoporosis, cigarette smoking, and exoge-
nous hormone use (oral contraceptive pill or hormone
replacement therapy) were not associated with statistically
1080 Breast Cancer Res Treat (2012) 133:1077–1088
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increased odds of invasive breast cancer. The univariable
OR for history of osteoporosis was 1.42 (95% CI
0.74–2.76, p = 0.30). The univariable OR for smoking
(upper quartile [C28 years] versus never smoking) was
1.12 (95% CI 0.74–1.70, p = 0.35), and for exogenous
hormone use (ever versus never) was 0.90 (95% CI
0.64–1.27, p = 0.54). History of osteoporosis, smoking,
and hormone use remained non-significant when included
in the multivariable model with suboptimal 25-hydroxy
vitamin-D, tamoxifen treatment, and BMI (C25.0 vs
\25.0 kg/m2). The OR for history of osteoporosis was 1.28
(95% CI 0.65–2.53, p = 0.48), the OR for smoking for at
least 28 years compared with never smoking was 1.15
(95% CI 0.75–1.76, p = 0.46), and the OR for prior hor-
mone use was 0.89 (95% CI 0.63–1.26, p = 0.51).
Menopausal status did not influence breast cancer risk in
either univariable or multivariable analyses (Supplemen-
tary Table). The adjusted OR for post-menopause was 0.90
(95% CI 0.51–1.58, p = 0.70, Supplemental Table-Model
3). There was also no significant interaction between BMI
and menopausal status (Supplemental Table-Model 4,
p = 0.32).
In univariable analyses and after adjusting for tamoxifen
treatment and BMI in multivariable modeling, plasma
levels of insulin, CRP, and leptin did not show statistically
significant effects on development of invasive breast can-
cer (Table 5, last three rows).
Meta-analysis of published studies assessing the asso-
ciation of blood levels of 25-hydroxy vitamin-D and breast
cancer showed variability. In all six studies where blood
levels of 25-hydroxy vitamin-D were measured after
diagnosis of breast cancer, there was a significant inverse
association between 25-hydroxy vitamin-D and breast
cancer. Pooled data showed a highly significant OR of 2.49
(95% CI 1.93–3.21, p \ 0.001). Among studies, where
levels were measured before breast cancer diagnosis, only
one out of nine studies showed a significant association
between levels of vitamin-D metabolites and breast cancer
and pooled data showed only limited association
(OR = 1.10, 95% CI 1.00–1.20, p = 0.04, Table 1;
Fig. 1 CONSORT diagram
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Table 2 Participant and tumor
characteristics among cases and
controls
Participant or tumor characteristic Total Cases Controls p*
N % N %
Age (years)
B49 470 96 41.6 374 43.7 0.84
50–59 299 66 28.6 233 27.2
C60 318 69 29.9 249 29.1
Treatment
Placebo 605 164 71.0 441 51.5 \.0001
Tamoxifen 482 67 29.0 415 48.5
5-year predicted breast cancer risk (%)
B2.24 300 64 27.7 236 27.6 0.99
2.25–3.48 293 63 27.3 230 26.9
C3.49 494 104 45.0 390 45.6
Body mass index
\25.0 444 79 34.2 365 42.6 0.02
C25.0 643 152 65.8 491 57.4
Smoking history (years)
None 592 117 50.6 475 55.5 0.33**
\18 173 35 15.2 138 16.1
18–27 143 39 16.9 104 12.1
C28 175 39 16.9 136 15.9
Unknown 4 1 0.4 3 0.4
History of hormone use
No 273 60 26.0 213 24.9 0.73
Yes 814 171 74.0 643 75.1
No. 1 relatives with breast cancer
0 220 47 20.3 173 20.2 0.41
1 605 121 52.4 484 56.5
C2 262 63 27.3 199 23.2
Menopausal status
Premenopausal 530 113 48.9 417 48.7 0.73
Postmenopausal 493 102 44.2 391 45.7
Unknown 64 16 6.9 48 5.6
History of breast atypical hyperplasia
No 986 204 88.3 782 91.4 0.16
Yes 101 27 11.7 74 8.6
History of osteoporosis
No 1034 216 93.5 818 95.6 0.20
Yes 53 15 6.5 38 4.4
25-Hydroxy vitamin-D concentration
\72 nmol/l 793 175 75.8 618 72.2 0.28
C72 nmol/l 294 56 24.2 238 27.8
Type of invasive cancer
Infiltrating duct carcinoma 171 171 74.0 – – –
Other 60 60 26.0 – –
Estrogen receptor status
Negative 56 56 24.2 – – –
Positive 158 158 68.4 – –
Unknown 17 17 7.4 – –
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Fig. 3). There was a statistically significant difference
between the two analysis subgroups (p \ 0.001).
Discussion
Recent research has focused on the identification and val-
idation of new risk factors predictive of breast cancer
occurrence. There has been substantial interest in host
factors such as obesity, vitamin-D status, adipocytokines,
and inflammation and immune function. 25-Hydroxy
vitamin-D concentrations have been related to factors
associated with increased risk of cancer including obesity,
circulating leptin levels [36], inflammatory markers [54],
and insulin resistance [20]. It has been hypothesized that
vitamin-D deficiency may explain increased cancer rates
[33]. However, a recent report from the Institute of Med-
icine suggested that there are limited data supporting the
association of vitamin-D status with cancer in general [43].
It remains unclear if any of the above-mentioned host
factors are independent predictors of breast cancer risk.
This study, conducted in a population of women at high
risk of breast cancer has shown that higher BMI was
associated with increased breast cancer risk. There was a
very weak, but statistically significant, negative correlation
of BMI with 25-hydroxy vitamin-D and moderate to strong
and significant positive correlations with insulin, CRP and
leptin levels. However, when adjusting for baseline BMI,
serum levels of 25-hydroxy vitamin-D, insulin, CRP and
leptin were not significantly associated with breast cancer.
It is unlikely that using different cut-offs for optimal
25-hydroxy vitamin-D would influence results as when
assessed as a continuous variable, 25-hydroxy vitamin-D
was also not seen to be associated with breast cancer risk.
Of interest, there was no evidence of interaction between
these factors and treatment. This suggests that these factors
are not independent predictors of breast cancer risk or
tamoxifen benefit in this high risk population.
The negative correlation between 25-hydroxy vitamin-D
and BMI has been described previously [38], and may be
explained by a volume-distribution effect with lower bio-
availability of fat-soluble vitamin-D metabolites in over-
weight and obese individuals with excess adipose tissue [49].
Table 3 Descriptive analysis of and correlations between serum variables
Variable Mean Standard deviation Spearman’s correlation rho*
25-Hydroxy vitamin-D Insulin CRP Leptin BMI
25-Hydroxy vitamin-D 57.9 25.3 – -0.23 -0.15 -0.22 -0.22
(nmol/l)
Insulin 53.4 50.0 -0.23 – 0.44 0.66 0.58
(pmol/l)
CRP 3.5 9.7 -0.15 0.44 – 0.53 0.54
(mg/l)
Leptin 29.6 21.7 -0.22 0.66 0.53 – 0.79
(lmol/l)
BMI 27.2 5.7 -0.22 0.58 0.54 0.79 –
(kg/m2)
* All correlations statistically significant at p \ 0.001
Table 2 continued
* p values are from v2 test
unless otherwise specified
** Fisher’s exact test
Participant or tumor characteristic Total Cases Controls p*
N % N %
Progesterone receptor status
Negative 85 85 36.8 – – –
Positive 123 123 53.2 – –
Unknown 23 23 10.0 – –
Presenting cancer stage
I 131 131 56.7 – – –
II 76 76 32.9 – –
III–IV 14 14 6.1 – –
Unknown 10 10 4.3 – –
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Positive correlations with insulin, leptin, and CRP have also
been reported previously and may relate to the cytokine
milieu associated with the metabolic syndrome [50]. No
correlation was seen between 25-hydroxy vitamin-D levels
and latitude of clinical center. This may be explained by the
clinical center only being a rough surrogate for latitude of
residence. Furthermore, no data were available on vitamin-D
supplementation and this may confound this geographic
analysis. However, a true absence of effect of latitude on
25-hydroxy vitamin-D levels in this population cannot be
excluded.
A number of factors may explain the inconsistent
association of blood levels of vitamin-D metabolites and
breast cancer. First, it is possible that findings are com-
promised by reverse causation bias. Our meta-analysis has
shown that significant association between vitamin-D
metabolites and breast cancer were predominantly seen in
studies where blood levels were collected after breast
cancer diagnosis. This cohort was significantly different
from the group where blood levels were collected before
breast cancer diagnosis where only limited association
between breast cancer and vitamin-D metabolite levels was
seen. Similar results have been reported in other pooled
analyses [7, 9, 52]. Analyses of blood drawn after breast
cancer diagnosis may be prone to error as the blood
parameter may be affected by the presence of breast can-
cer. Breast cancer cells have been shown to possess vita-
min-D catalytic enzymes [18, 45] and these may interfere
with standard 25-hydroxy vitamin-D assay techniques.
Second, patients diagnosed with breast cancer may modify
their lifestyle (such as diet, dietary supplementation,
physical activity, and/or sun exposure), and this may lead
to post-diagnosis changes in vitamin-D metabolite levels.
Finally, the duration of follow-up for patients included in
this analysis was less than 55 months. It is possible that this
duration was not sufficiently long to observe the effects of
blood levels of vitamin-D and cancer risk.
Prophylactic therapy with tamoxifen was protective of
breast cancer with an OR of 0.44. This was consistent with
the whole NSABP-P1 population suggesting balanced
sampling of cases and controls. Consistent with prior data
[31], higher BMI was shown to lead to increased breast
cancer. Overweight and obese patients (BMI [ 25 kg/m2)
had a statistically significant relative increase in the odds of
breast cancer of 45%. A number of mechanisms have been
suggested for this association. It has been proposed that
obesity is associated with insulin resistance and hyperin-
sulinemia [42]. Our data suggest that the level of insulin
does not influence cancer risk in this high risk population,
and therefore implies that other, perhaps unknown
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Fig. 2 Correlations between BMI and 25-hydroxy vitamin-D, insulin, CRP, and leptin
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Table 5 Univariable and multivariable analyses of the association of log transformed plasma levels of 25-hydroxy vitamin-D, insulin, CRP, and
leptin with invasive breast cancer
Adjustment variables Variable assessed Comparison* Odds ratio 95% CI p
None 25-Hydroxy vitamin-D (nmol/l) 86 vs. 31 0.77 0.55–1.06 0.11
Insulin (pmol/l) 87 vs. 22 1.04 0.76–1.44 0.79
CRP (mg/l) 6.5 vs. 0.4 1.05 0.85–1.30 0.64
Leptin (lmol/l) 53.1 vs. 9.8 1.38 0.99–1.93 0.052
Treatment 25-Hydroxy vitamin-D (nmol/l) 86 vs. 31 0.81 0.58–1.13 0.23
Insulin (pmol/l) 87 vs. 22 1.03 0.75–1.43 0.84
CRP (mg/l) 6.5 vs. 0.4 1.07 0.86–1.33 0.53
Leptin (lmol/l) 53.1 vs. 9.8 1.37 0.98–1.92 0.07
Treatment and BMI 25-Hydroxy vitamin-D (nmol/l) 86 vs. 31 0.86 0.62–1.21 0.40
Insulin (pmol/l) 87 vs. 22 0.84 0.58–1.21 0.34
CRP (mg/l) 6.5 vs. 0.4 0.95 0.75–1.21 0.68
Leptin (lmol/l) 53.1 vs. 9.8 1.09 0.71–1.68 0.70
* Midpoint of the upper quartile to the midpoint of the lower quartile
Table 4 Univariable and
multivariable analysis of the
association of 25-hydroxy
vitamin-D with invasive breast
cancer
Model number Variables in model Odds ratio 95% CI for odds ratio p value
Model 1 25-Hydroxy vitamin-D
\72 nmol/l 1.25 0.88–1.77 0.21
C72 nmol/l 1.00
Model 2 25-Hydroxy vitamin-D
\72 nmol/l 1.14 0.79–1.63 0.48
C72 nmol/l 1.00
Treatment
Placebo 1.00
Tamoxifen 0.45 0.33–0.61 \0.001
Model 3 25-Hydroxy vitamin-D
\72 nmol/l 1.06 0.73–1.53 0.76
C72 nmol/l 1.00
Treatment
Placebo 1.00
Tamoxifen 0.44 0.32–0.61 \0.001
Body mass index
\25.0 1.00
C25.0 1.45 1.06–2.00 0.02
Model 4 25-Hydroxy vitamin-D
\72 nmol/l 1.07 0.74–1.54 0.73
C72 nmol/l 1.00
Treatment
Placebo 1.00
Tamoxifen 0.44 0.32–0.61 \0.001
Body mass index
\25.0 1.00
25.0–29.9 1.51 1.06–2.15
C30.0 1.38 0.93–2.03 0.06
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mechanisms may explain the association of BMI and breast
cancer risk. The association of BMI and breast cancer has
been predominantly seen in post-menopausal women, and
has also been observed in pre-menopausal women with
central obesity [27]. In our study, 49% of patients were pre-
menopausal. An analysis of the interaction between BMI
and menopausal status was not significant. However, as
cases and controls were matched for age and this variable is
highly correlated with menopausal status, it is difficult to
interpret these findings accurately.
Inflammation has been associated with increased risk of
breast cancer [10, 39]. CRP is a marker of systemic
inflammation, but data on its association with breast cancer
risk remains sparse. Our data showed that baseline CRP did
not predict for increased breast cancer risk. Similar data
were reported in an analysis of the Women’s Health Study
[53]. Both these analyses were limited by single mea-
surements of CRP which likely does not reflect long-term
levels of inflammation. This limitation leads to uncertainty
in the assessment of the association between inflammation
and breast cancer risk.
These data have limitations. First, blood samples were
collected from patients at only one time point. Therefore, these
may not reflect levels of key mediators over time. Second,
despite a large cohort population, the number of breast cancers
was relatively small. This may have been influenced by our
inclusion of only events occurring before unblinding of the
study. Such case matching of a small subgroup of patients
from a large randomized trial may be criticized. However, this
was the only feasible methodology because after unblinding,
patients on placebo were offered cross-over or enrolment on a
randomized trial of tamoxifen versus raloxifene. It is hoped
that the comprehensive background information and follow-
up data derived from a randomized trial will negate these
methodologic weaknesses. Third, due to matching by age, the
differential effect of the tested blood levels in pre- and post-
menopausal women could not be assessed robustly. Such
analyses could also be confounded by pre-study use of hor-
mone replacement therapy, although in our data, this variable
did not appear to significantly affect breast cancer risk. Fourth,
our choice of 25-hydroxy vitamin-D assay can be criticized.
There can be substantial inter-assay differences in perfor-
mance between different 25-hydroxy vitamin-D platforms
[46], although these different methods have acceptable cor-
relation [32]. Mass spectrometry-based assays likely results in
the best calibration [46], but are not commonly used in clinical
practice. Therefore, our use of electrochemiluminescence
would likely have resulted in a balance between limited
internal validity, but robust external validity. Finally, the
population of women included in this study was at high risk for
developing invasive breast cancer, and therefore may not be
representative of all women. Despite these limitations, the
meta-analysis shows that our findings are consistent with
those from other studies where blood was collected before
breast cancer diagnosis. These consistent findings which are
not prone to reverse causation bias are likely to be a more
accurate assessment of the association of vitamin-D metabo-
lites and breast cancer risk.
In summary, when controlling for Gail score and
adjusting for other factors independently associated with
the risk of developing invasive breast cancer, suboptimal
baseline levels of 25-hydroxy vitamin-D and increased
Fig. 3 Forest plot of odds
ratios for breast cancer risk
comparing low to high blood
levels of vitamin-D metabolites.
Odds ratios for each study are
represented by the squares, the
size of the square represents the
weight of the trial in the meta-
analysis, and the horizontal line
crossing the square represents
the 95% confidence interval.
The diamonds represent the
estimated pooled effect based
on each cohort individually
(labeled sub-total) and for all
cohorts together (labeled total).
Test of subgroup differences
relates to the test of
heterogeneity between the two
subgroups as defined by Deeks
et al. [14]. All p values are
two-sided
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baseline levels of insulin, CRP, and leptin levels do not show
independent associations with the risk of breast cancer. BMI
is a strong predictor of breast cancer, but the mechanisms
underlying this association remain unclear. Further prospec-
tive data are required to further define how obesity influences
breast cancer risk.
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